NASDAQ:PRTO - Proteon Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.98
▼ -0.13 (-4.18%)
Get New Proteon Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRTO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRTO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Proteon Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $2.98.

This chart shows the closing price for PRTO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Proteon Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2019CowenReiterated RatingHoldHigh
3/29/2019Robert W. BairdLower Price TargetNeutral ➝ Neutral$3.00 ➝ $1.00Low
3/28/2019Maxim GroupDowngradeBuy ➝ HoldHigh
3/28/2019JMP SecuritiesDowngradeMarket PerformHigh
3/18/2019HC WainwrightBoost Price TargetBuy ➝ Positive$3.00 ➝ $4.00Medium
3/7/2019Maxim GroupSet Price TargetBuy$5.00High
2/11/2019JMP SecuritiesUpgradeMarket Perform ➝ OutperformHigh
1/25/2019HC WainwrightSet Price TargetBuy$3.00Medium
10/30/2018Maxim GroupInitiated CoverageBuy ➝ Buy$5.00Low
6/26/2018Brookline Capital ManagementReiterated RatingBuyMedium
5/10/2018CowenReiterated RatingHoldLow
5/10/2018HC WainwrightUpgradeNeutral ➝ Buy$3.00Low
3/16/2018HC WainwrightSet Price TargetHold$2.00High
3/15/2018Robert W. BairdReiterated RatingOutperformHigh
3/14/2018Robert W. BairdSet Price TargetOutperform ➝ Hold$2.00 ➝ $3.00High
11/10/2017Robert W. BairdReiterated RatingHold$2.00N/A
11/8/2017HC WainwrightReiterated RatingHold$2.30N/A
8/16/2017OppenheimerReiterated RatingMarket PerformLow
8/9/2017HC WainwrightSet Price TargetHold$2.00Low
8/8/2017CowenReiterated RatingHoldLow
(Data available from 7/1/2017 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/3/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/1/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/3/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/2/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/1/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/1/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Proteon Therapeutics logo
Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $2.98
Low: $2.91
High: $3.14

50 Day Range

MA: $19.37
Low: $0.84
High: $25.13

52 Week Range

Now: $2.98
Low: $0.22
High: $3.94

Volume

157,590 shs

Average Volume

1,113,217 shs

Market Capitalization

$66.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Proteon Therapeutics?

The following sell-side analysts have issued reports on Proteon Therapeutics in the last twelve months:
View the latest analyst ratings for PRTO.

What is the current price target for Proteon Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Proteon Therapeutics in the last year.
View the latest price targets for PRTO.

What is the current consensus analyst rating for Proteon Therapeutics?

Proteon Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PRTO.

How do I contact Proteon Therapeutics' investor relations team?

Proteon Therapeutics' physical mailing address is 200 WEST STREET, WALTHAM MA, 02451. The biopharmaceutical company's listed phone number is 781-890-0102 and its investor relations email address is [email protected] The official website for Proteon Therapeutics is www.proteontherapeutics.com. Learn More about contacing Proteon Therapeutics investor relations.